MGMT Expression and Gene Variants in Melanoma Chemotherapy Response
Author Information
Author(s): Ma S, Egyházi S, Ueno T, Lindholm C, Kreklau E L, Stierner U, Ringborg U, Hansson J
Primary Institution: Cancer Centre Karolinska, Karolinska Hospital, Stockholm, Sweden
Hypothesis
Does O6-methylguanine-DNA-methyltransferase (MGMT) expression and its gene polymorphisms affect the response to chemotherapy in metastatic melanoma?
Conclusion
Higher MGMT expression is associated with poorer response to DTIC-based chemotherapy in metastatic melanoma patients.
Supporting Evidence
- MGMT expression varied considerably among different melanoma tumors.
- Patients with low MGMT expression had a higher response rate to chemotherapy.
- The study included a total of 110 biopsies from 79 patients.
Takeaway
This study found that patients with lower levels of a specific protein (MGMT) in their tumors responded better to a common melanoma treatment.
Methodology
The study analyzed tumor biopsies from 79 patients, assessing MGMT expression and gene polymorphisms in relation to chemotherapy response.
Potential Biases
Potential bias due to varying treatment regimens and the retrospective nature of clinical response data collection.
Limitations
The study's findings may be influenced by tumor heterogeneity and the small number of patients treated with DTIC alone.
Participant Demographics
47 male and 32 female patients with a median age of 58 years (range 22–83 years).
Statistical Information
P-Value
0.05
Statistical Significance
p=0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website